ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 353.1 | 342.4 | 293.7 |
| Other income | 4.1 | 2.2 | 1.4 |
| Total income | 357.2 | 344.7 | 295.1 |
| Profit before exceptional items & tax | 54.5 | 74.3 | 43.4 |
| Exceptional items | 0.0 | -19.1 | 0.0 |
| Profit before tax | 54.7 | 55.2 | 43.6 |
| Net profit | 45.3 | 41.3 | 31.6 |
| Operating margin | 15.3% | 16.0% | 14.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +43.40% |
|---|---|
| Net profit, quarter on quarter | +9.70% |
| Revenue, year on year | +20.20% |
NSE results filing, NSE: CORONA. Figures extracted from the filing.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,387.30
- Market cap
- ₹14,601 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 70.5×Sector 43.8×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Legal & Regulatory
Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.
- Value
- ₹4.88 Cr
Corona Remedies Earnings Call Transcript: Key Takeaways
CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.
- Call
- Guides 15% growth
Corona Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.3 Cr · +15.3% YoY
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.